There is provided a compound exhibiting an activity of suppressing immune response with reduced adverse
drug reactions, which compound is useful in the
chemotherapy for preventing or treating, for example, a wide range of various autoimmune diseases including systemic erythematodes, chronic
rheumatoid arthritis,
Type I diabetes,
inflammatory bowel disease, biliary
cirrhosis,
uveitis,
multiple sclerosis or other disorders, or chronic inflammatory diseases, or cancers,
lymphoma or
leukemia, or resistance to organ or
tissue transplantation or rejection against
transplantation.Novel amine compounds having an S1P1 / Edg1
receptor agonist effect, possible stereoisomers or racemic bodies of the compounds, or pharmacologically acceptable salts, hydrates or solvates of the compound, the stereoisomers or the racemic bodies, or prodrugs of the compounds, the stereoisomers, the racemic bodies, the salts, the hydrates or the solvates, are provided.